KU004 is a novel quinazoline-based dual EGFR/HER2 inhibitor. It demonstrates anticancer activity by blocking HER2/EGFR and downstream Akt/Erk signaling, inducing G1 arrest and extrinsic apoptosis in SKBR3 breast cancer cells in vitro. This mechanism supports its research use in studying targeted oncology pathways.